Home / Health / Weight-Loss Drugs May Worsen ALS, Doctors Warn
Weight-Loss Drugs May Worsen ALS, Doctors Warn
16 Jul
Summary
- GLP-1 agonists used for weight loss may speed up ALS progression.
- Maintaining weight is crucial for preserving nerve and muscle function in ALS.
- A case study showed rapid decline stabilized after stopping semaglutide.
Neurologists are expressing concerns that popular GLP-1 receptor agonist medications, widely prescribed for diabetes and weight management, may adversely affect individuals with neurodegenerative conditions like amyotrophic lateral sclerosis (ALS).
Jinsy Andrews, MD, a neurologist at NYU Langone, explained that the weight-loss effects of these drugs can be detrimental to ALS patients. Standard care for ALS often advises patients to maintain or even increase their body weight to support remaining nerve and muscle function.
Evidence from a 2025 case report detailed a 52-year-old ALS patient experiencing rapid physical decline after starting semaglutide for type 2 diabetes. Following a 25-pound weight loss in three months, her symptoms worsened dramatically. The patient’s condition stabilized once the medication was stopped, underscoring the need for careful consideration of GLP-1 agonists in ALS patients.
